# Safety and Efficacy of Zanubrutinib in the Treatment of Antiphospholipid Syndrome With Secondary Thrombocytopenia

> **NCT05199909** · PHASE2 · RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 10 (estimated)

## Conditions studied

- Antiphospholipid Syndrome
- Thrombocytopenia
- Treatment

## Interventions

- **DRUG:** zanubrutinib

## Key facts

- **NCT ID:** NCT05199909
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-01-25
- **Primary completion:** 2023-12-31
- **Final completion:** 2025-06-30
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2025-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05199909

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05199909, "Safety and Efficacy of Zanubrutinib in the Treatment of Antiphospholipid Syndrome With Secondary Thrombocytopenia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05199909. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*